Kinnate Biopharma Inc
NASDAQ:KNTE
Intrinsic Value
Kinnate Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. [ Read More ]
The intrinsic value of one KNTE stock under the Base Case scenario is 2.45 USD. Compared to the current market price of 2.65 USD, Kinnate Biopharma Inc is Overvalued by 7%.
Valuation Backtest
Kinnate Biopharma Inc
Run backtest to discover the historical profit from buying and selling KNTE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Kinnate Biopharma Inc
Current Assets | 158.2m |
Cash & Short-Term Investments | 154m |
Other Current Assets | 4.1m |
Non-Current Assets | 15.4m |
Long-Term Investments | 10.3m |
PP&E | 4.8m |
Other Non-Current Assets | 409k |
Current Liabilities | 12m |
Accounts Payable | 2m |
Accrued Liabilities | 10m |
Non-Current Liabilities | 2.3m |
Other Non-Current Liabilities | 2.3m |
Earnings Waterfall
Kinnate Biopharma Inc
Revenue
|
0
USD
|
Operating Expenses
|
-119m
USD
|
Operating Income
|
-119m
USD
|
Other Expenses
|
6.4m
USD
|
Net Income
|
-112.6m
USD
|
Free Cash Flow Analysis
Kinnate Biopharma Inc
KNTE Profitability Score
Profitability Due Diligence
Kinnate Biopharma Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Kinnate Biopharma Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
KNTE Solvency Score
Solvency Due Diligence
Kinnate Biopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Kinnate Biopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KNTE Price Targets Summary
Kinnate Biopharma Inc
According to Wall Street analysts, the average 1-year price target for KNTE is 2.41 USD with a low forecast of 2.02 USD and a high forecast of 2.72 USD.
Ownership
KNTE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
KNTE Price
Kinnate Biopharma Inc
Average Annual Return | -40.96% |
Standard Deviation of Annual Returns | 32.35% |
Max Drawdown | -98% |
Market Capitalization | 124.9m USD |
Shares Outstanding | 47 094 882 |
Percentage of Shares Shorted | 1.55% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Kinnate Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-03. The Company’s products include KIN-2787, KIN-3248 and KIN004. The KIN-2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations that characterize subsets of lung cancer, melanoma and other solid tumors. The firm has initiated a Phase I clinical trial for KIN-2787 (KN-8701). KIN-3248 is a small-molecule kinase inhibitor targeting cancer-associated alterations in FGFR2 and FGFR3 genes. KIN-3248 address the initial alteration and clinically-observed and predicted mutations in FGFR2 fusion gene-positive intrahepatic cholangiocarcinoma (ICC) and FGFR3-altered ulcerative colitis (UC). CDK12 inhibitor candidate to target the treatment of ovarian carcinoma (OC), metastatic castration-resistant prostate cancer (mCRPC) and triple-negative breast cancer (TNBC).
Contact
IPO
Employees
Officers
The intrinsic value of one KNTE stock under the Base Case scenario is 2.45 USD.
Compared to the current market price of 2.65 USD, Kinnate Biopharma Inc is Overvalued by 7%.